Annual EBITDA
-$4.05 M
+$39.21 M+90.64%
31 December 2023
Summary:
Akebia Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$4.05 million, with the most recent change of +$39.21 million (+90.64%) on 31 December 2023. During the last 3 years, it has risen by +$341.12 million (+98.83%). AKBA annual EBITDA is now at all-time high.AKBA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$4.00 M
-$6.98 M-234.50%
30 September 2024
Summary:
Akebia Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$4.00 million, with the most recent change of -$6.98 million (-234.50%) on 30 September 2024. Over the past year, it has dropped by -$332.00 thousand (-9.04%). AKBA quarterly EBITDA is now -109.12% below its all-time high of $43.91 million, reached on 30 June 2022.AKBA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$4.30 M
-$332.00 K-7.17%
30 September 2024
Summary:
Akebia Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently $4.30 million, with the most recent change of -$332.00 thousand (-7.17%) on 30 September 2024. Over the past year, it has increased by +$19.01 million (+129.20%). AKBA TTM EBITDA is now -7.17% below its all-time high of $4.63 million, reached on 30 June 2024.AKBA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AKBA EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +90.6% | -9.0% | +129.2% |
| 3 y3 years | +98.8% | +91.1% | +101.7% |
| 5 y5 years | +97.7% | +91.3% | +101.7% |
AKBA EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +98.8% | -109.1% | +93.1% | -7.2% | +101.7% |
| 5 y | 5 years | at high | +98.8% | -109.1% | +97.6% | -7.2% | +101.2% |
| alltime | all time | at high | +98.8% | -109.1% | +97.6% | -7.2% | +101.2% |
Akebia Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$4.00 M(-234.5%) | $4.30 M(-7.2%) |
| June 2024 | - | $2.98 M(-148.7%) | $4.63 M(+202.7%) |
| Mar 2024 | - | -$6.11 M(-153.4%) | $1.53 M(-118.5%) |
| Dec 2023 | -$4.05 M(-90.6%) | $11.44 M(-411.4%) | -$8.27 M(-43.8%) |
| Sept 2023 | - | -$3.67 M(+2885.4%) | -$14.72 M(-71.6%) |
| June 2023 | - | -$123.00 K(-99.2%) | -$51.77 M(+569.7%) |
| Mar 2023 | - | -$15.91 M(-419.1%) | -$7.73 M(-80.6%) |
| Dec 2022 | -$43.26 M(-81.1%) | $4.98 M(-112.2%) | -$39.76 M(-61.2%) |
| Sept 2022 | - | -$40.72 M(-192.7%) | -$102.48 M(-4.0%) |
| June 2022 | - | $43.91 M(-191.6%) | -$106.73 M(-51.3%) |
| Mar 2022 | - | -$47.93 M(-17.0%) | -$219.21 M(-3.2%) |
| Dec 2021 | -$228.37 M(-33.8%) | -$57.74 M(+28.4%) | -$226.53 M(-8.6%) |
| Sept 2021 | - | -$44.98 M(-34.4%) | -$247.89 M(-2.4%) |
| June 2021 | - | -$68.57 M(+24.1%) | -$253.98 M(-27.3%) |
| Mar 2021 | - | -$55.25 M(-30.1%) | -$349.24 M(+1.8%) |
| Dec 2020 | -$345.17 M(+38.1%) | -$79.10 M(+54.9%) | -$343.13 M(-1.7%) |
| Sept 2020 | - | -$51.06 M(-68.8%) | -$349.24 M(+1.4%) |
| June 2020 | - | -$163.82 M(+233.3%) | -$344.35 M(+49.5%) |
| Mar 2020 | - | -$49.15 M(-42.3%) | -$230.36 M(-7.0%) |
| Dec 2019 | -$249.87 M(+42.2%) | -$85.20 M(+84.5%) | -$247.64 M(-1.3%) |
| Sept 2019 | - | -$46.17 M(-7.4%) | -$250.81 M(+8.0%) |
| June 2019 | - | -$49.84 M(-25.0%) | -$232.26 M(+6.6%) |
| Mar 2019 | - | -$66.43 M(-24.8%) | -$217.87 M(+24.0%) |
| Dec 2018 | -$175.74 M | -$88.38 M(+220.0%) | -$175.74 M(+142.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$27.62 M(-22.1%) | -$72.56 M(+5.2%) |
| June 2018 | - | -$35.45 M(+45.9%) | -$68.95 M(+24.2%) |
| Mar 2018 | - | -$24.30 M(-264.1%) | -$55.52 M(-27.0%) |
| Dec 2017 | -$76.06 M(-44.1%) | $14.81 M(-161.7%) | -$76.06 M(-40.9%) |
| Sept 2017 | - | -$24.01 M(+9.0%) | -$128.78 M(-8.6%) |
| June 2017 | - | -$22.02 M(-50.9%) | -$140.86 M(-9.1%) |
| Mar 2017 | - | -$44.84 M(+18.2%) | -$154.99 M(+13.8%) |
| Dec 2016 | -$136.16 M(+121.7%) | -$37.92 M(+5.1%) | -$136.16 M(+15.1%) |
| Sept 2016 | - | -$36.09 M(-0.1%) | -$118.28 M(+16.1%) |
| June 2016 | - | -$36.14 M(+38.9%) | -$101.84 M(+33.0%) |
| Mar 2016 | - | -$26.01 M(+29.8%) | -$76.55 M(+24.6%) |
| Dec 2015 | -$61.42 M(+62.1%) | -$20.04 M(+2.0%) | -$61.42 M(+18.2%) |
| Sept 2015 | - | -$19.64 M(+80.9%) | -$51.97 M(+24.0%) |
| June 2015 | - | -$10.86 M(-0.2%) | -$41.90 M(+7.8%) |
| Mar 2015 | - | -$10.88 M(+2.7%) | -$38.87 M(+2.6%) |
| Dec 2014 | -$37.89 M(+137.8%) | -$10.59 M(+10.7%) | -$37.89 M(+13.1%) |
| Sept 2014 | - | -$9.57 M(+22.3%) | -$33.50 M(+19.8%) |
| June 2014 | - | -$7.83 M(-20.9%) | -$27.96 M(+20.2%) |
| Mar 2014 | - | -$9.90 M(+59.7%) | -$23.26 M(+46.0%) |
| Dec 2013 | -$15.93 M(+86.9%) | -$6.20 M(+53.7%) | -$15.93 M(+63.7%) |
| Sept 2013 | - | -$4.03 M(+29.3%) | -$9.73 M(+70.8%) |
| June 2013 | - | -$3.12 M(+21.1%) | -$5.70 M(+121.1%) |
| Mar 2013 | - | -$2.58 M | -$2.58 M |
| Dec 2012 | -$8.52 M | - | - |
FAQ
- What is Akebia Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Akebia Therapeutics?
- What is Akebia Therapeutics annual EBITDA year-on-year change?
- What is Akebia Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Akebia Therapeutics?
- What is Akebia Therapeutics quarterly EBITDA year-on-year change?
- What is Akebia Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Akebia Therapeutics?
- What is Akebia Therapeutics TTM EBITDA year-on-year change?
What is Akebia Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of AKBA is -$4.05 M
What is the all time high annual EBITDA for Akebia Therapeutics?
Akebia Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$4.05 M
What is Akebia Therapeutics annual EBITDA year-on-year change?
Over the past year, AKBA annual earnings before interest, taxes, depreciation & amortization has changed by +$39.21 M (+90.64%)
What is Akebia Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of AKBA is -$4.00 M
What is the all time high quarterly EBITDA for Akebia Therapeutics?
Akebia Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $43.91 M
What is Akebia Therapeutics quarterly EBITDA year-on-year change?
Over the past year, AKBA quarterly earnings before interest, taxes, depreciation & amortization has changed by -$332.00 K (-9.04%)
What is Akebia Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of AKBA is $4.30 M
What is the all time high TTM EBITDA for Akebia Therapeutics?
Akebia Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $4.63 M
What is Akebia Therapeutics TTM EBITDA year-on-year change?
Over the past year, AKBA TTM earnings before interest, taxes, depreciation & amortization has changed by +$19.01 M (+129.20%)